Capricor Therapeutics (NASDAQ:CAPR) Releases Earnings Results, Meets Expectations

Capricor Therapeutics (NASDAQ:CAPR) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.54), Zacks reports.

Capricor Therapeutics Trading Down 6.2%

Shares of CAPR traded down $0.37 during midday trading on Monday, reaching $5.56. 3,831,050 shares of the stock were exchanged, compared to its average volume of 1,837,837. The company has a market capitalization of $254.19 million, a P/E ratio of -3.39 and a beta of 0.57. Capricor Therapeutics has a 52 week low of $5.43 and a 52 week high of $20.75. The company’s 50 day moving average is $6.57 and its two-hundred day moving average is $8.38.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CAPR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Monday, July 14th. HC Wainwright restated a “buy” rating and set a $24.00 target price on shares of Capricor Therapeutics in a research report on Thursday, September 25th. Finally, Roth Capital dropped their price objective on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating for the company in a report on Monday, July 14th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.25.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently modified their holdings of CAPR. Jump Financial LLC increased its holdings in Capricor Therapeutics by 42.6% during the second quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock valued at $2,309,000 after buying an additional 69,515 shares during the period. Goldman Sachs Group Inc. boosted its position in Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after acquiring an additional 116,373 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Capricor Therapeutics by 2,342.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 36,398 shares of the biotechnology company’s stock valued at $361,000 after acquiring an additional 34,908 shares during the period. Marshall Wace LLP bought a new position in shares of Capricor Therapeutics in the 2nd quarter worth $796,000. Finally, Rhumbline Advisers lifted its stake in shares of Capricor Therapeutics by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock worth $531,000 after purchasing an additional 3,636 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.